Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bone Growth Factor Market Offers Attractive Niche For Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Medtronic/Sofamor Danek expects to submit clinical data supporting a premarket approval application for its InFuse BMP-2 recombinant bone morphogenic protein by mid-year. The company is hoping for expedited FDA review of the product, with a possible rollout by 2002.

You may also be interested in...



Stryker Will Discuss Rejected OP-1 PMA At Upcoming Meeting With FDA

Stryker expects to meet with FDA by March 1 to discuss the agency's "not approvable" letter for OP-1 bone growth factor for treating nonunion fractures.

Stryker Will Discuss Rejected OP-1 PMA At Upcoming Meeting With FDA

Stryker expects to meet with FDA by March 1 to discuss the agency's "not approvable" letter for OP-1 bone growth factor for treating nonunion fractures.

OrthoLogic Rehab Divestiture Will Fund Chrysalin Osteobiologics Development

OrthoLogic is planning to divest its $60 mil. orthopedic rehabilitation device business and use the proceeds for further development of the osteobiologic product Chrysalin, and to expand the company's remaining fracture healing and spinal repair business, including possible acquisitions.

Related Content

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel